Drug Trial Radar · NCT02682264
An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Nov 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
609
Actual
Start
Mar 9, 2016
Primary completion
Aug 31, 2018
Study completion Aug 31, 2018
Sponsor
- Lead sponsor
- Cassiopea SpAIndustry
- Sponsor type
- Industry
- First posted
- Feb 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the long-term safety of CB-03-01 cream, 1% applied twice daily for an additional nine months in study participants with acne vulgaris that participated in the Phase 3 pivotal studies for a total treatment of up to 12 months.
Conditions
- Acne Vulgaris
Interventions
CB-03-01 cream, 1%Drug
Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Local and Systemic Treatment Emergent Adverse EventsTime frame: up to 52 weeks
Locations
74 sites in 7 countries. Site status is shown where the registry gives one.
Johnson Dermatology
Fort Smith, Arkansas
Gary M. Petrus, MD PA
Little Rock, Arkansas
Center for Dermatology and Laser Surgery
Sacramento, California
Rady Childrens Hospital, Pediatric and Adolescent Dermatology
San Diego, California
Southern California Dermatology
Santa Ana, California
Clinical Science Institute
Santa Monica, California
Memorial Research Medical Clinic dba / Orange County Research Center
Tustin, California
Horizons Clinical Research Center, LLC
Denver, Colorado
Study Protocol, Inc.
Boynton Beach, Florida
Tory Sullivan, M.D., P.A.
North Miami Beach, Florida
Belleair Research Center
Pinellas Park, Florida
Meridien Research
St. Petersburg, Florida
MOORE Clinical Research, Inc.
Tampa, Florida
MedaPhase, Inc.
Newnan, Georgia
Arlington Dermatology
Arlington Heights, Illinois
Shideler Clinical Research Center
Carmel, Indiana
The Indiana Clinical Trials Center
Plainfield, Indiana
Kansas City Dermatology, PA
Overland Park, Kansas
Maryland Laser Skin and Vein Institute
Hunt Valley, Maryland
Henry Ford Health System
Detroit, Michigan
MediSearch Clinical Trials
Saint Joseph, Missouri
Sadick Research Group, LLC
New York, New York
Skin Specialty Dermatology
New York, New York
DermResearch Center of New York, Inc.
Stony Brook, New York
Oregon Dermatology and Research Center
Portland, Oregon
The Pennsylvania State University and the Milton S. Hershey Medical Center
Hershey, Pennsylvania
Clinical Partners, LLC
Johnston, Rhode Island
Omega Medical Research
Warwick, Rhode Island
Greenville Dermatology, LLC
Greenville, South Carolina
International Clinical Research - Tennessee LLC
Murfreesboro, Tennessee
Tennessee Clinical Research Center
Nashville, Tennessee
Westlake Dermatology Clinical Research Center
Austin, Texas
The University of Texas Health Science Center at Houston
Houston, Texas
Austin Institute for Clinical Research, Inc.
Pflugerville, Texas
Texas Dermatology and Laser Specialists
San Antonio, Texas
Progressive Clinical Research, PA
San Antonio, Texas
Clinical Research Associates of Tidewater, Inc.
Norfolk, Virginia
Dermatology Associates
Seattle, Washington
Premier Clinical Research
Spokane, Washington
Site 3521
Plovdiv, Bulgaria
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.